A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. 1996

S L McElroy, and P E Keck, and S P Stanton, and K C Tugrul, and J A Bennett, and S M Strakowski
Department of Psychiatry, University of Cincinnati College of Medicine, Ohio, 45267, USA.

BACKGROUND Uncontrolled evidence suggests that divalproex administered via the oral loading strategy of 20 mg/kg/day may produce clinically significant antimanic response within 3 days of treatment in some patients. We conducted a prospective study to compare the antimanic response of divalproex oral loading with that of haloperidol in the initial treatment of acute psychotic mania. METHODS After a < or = 1-day screening period, 36 consecutive hospitalized patients with bipolar disorder, manic or mixed phase and with psychotic features, were randomly assigned to receive either divalproex 20 mg/kg/day or haloperidol 0.2 mg/kg/day for 6 full days, without other psychotropic agents except lorazepam up to 4 mg/day for management of agitation. Serum valproate concentrations were measured after 1 day of treatment. Response was measured daily by a blind rater using the Young Mania Rating Scale and the Scale for Assessment of Positive Symptoms. RESULTS Divalproex oral loading and haloperidol were equally effective in acutely reducing manic and psychotic symptoms. The greatest rate of improvement for both drug regimens occurred over the first 3 full days of treatment. Side effects were infrequent and minor for both treatments, except for extrapyramidal side effects which were significantly more common with haloperidol. CONCLUSIONS Divalproex oral loading may produce rapid onset of antimanic and antipsychotic response comparable to that of haloperidol and with minimal side effects in the initial treatment of acute psychotic mania in a subset of bipolar patients.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006760 Hospitalization The confinement of a patient in a hospital. Hospitalizations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001480 Basal Ganglia Diseases Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA. Extrapyramidal Disorders,Basal Ganglia Disorders,Lenticulostriate Disorders,Basal Ganglia Disease,Basal Ganglia Disorder,Extrapyramidal Disorder,Lenticulostriate Disorder

Related Publications

S L McElroy, and P E Keck, and S P Stanton, and K C Tugrul, and J A Bennett, and S M Strakowski
January 1998, Depression and anxiety,
S L McElroy, and P E Keck, and S P Stanton, and K C Tugrul, and J A Bennett, and S M Strakowski
June 2002, The American journal of psychiatry,
S L McElroy, and P E Keck, and S P Stanton, and K C Tugrul, and J A Bennett, and S M Strakowski
January 2005, General hospital psychiatry,
S L McElroy, and P E Keck, and S P Stanton, and K C Tugrul, and J A Bennett, and S M Strakowski
March 2004, The Journal of clinical psychiatry,
S L McElroy, and P E Keck, and S P Stanton, and K C Tugrul, and J A Bennett, and S M Strakowski
June 2008, The Journal of clinical psychiatry,
S L McElroy, and P E Keck, and S P Stanton, and K C Tugrul, and J A Bennett, and S M Strakowski
October 2003, The Journal of clinical psychiatry,
S L McElroy, and P E Keck, and S P Stanton, and K C Tugrul, and J A Bennett, and S M Strakowski
January 2003, Clinical drug investigation,
S L McElroy, and P E Keck, and S P Stanton, and K C Tugrul, and J A Bennett, and S M Strakowski
January 1982, Acta psychiatrica Belgica,
S L McElroy, and P E Keck, and S P Stanton, and K C Tugrul, and J A Bennett, and S M Strakowski
April 2010, The Journal of clinical psychiatry,
S L McElroy, and P E Keck, and S P Stanton, and K C Tugrul, and J A Bennett, and S M Strakowski
October 2006, The Journal of clinical psychiatry,
Copied contents to your clipboard!